Affective Changes Associated with L-DOPA Therapy

  • H. Keith Brodie
Part of the Advances in Behavioral Biology book series (ABBI, volume 6)


The dramatic therapeutic effects of L-DOPA in the treatment of Parkinson’s disease have focused attention on psychiatric changes accompanying the administration of this compound (1). While the neurologists were busy studying the effects of DOPA in patients with extrapyramidal disorders, the psychiatrists were assessing the efficacy of L-DOPA in the treatment of depression (2). Based on the hypothesis that depression may be associated with a deficiency in catecholamines proposed by Bunney, Davis, and Schildkraut in the mid-Sixties (3,4), several research groups attempted to administer L-DOPA to depressed patients in order to reverse the presumed deficit in dopamine or norepinephrine (2,5). This paper reviews several of these studies, emphasizing some of the human mood changes associated with the administration of L-DOPA, as well as some of the biochemical effects of this compound. This discussion is particularly relevant in a conference on aging, because most of the patients who will be receiving L-DOPA for the treatment of Parkinson’s disease are patients who are sixty years old or older, some of whom will have a mood change caused by the administration of L-DOPA. Most of the data reviewed in this chapter has been published elsewhere (6).


Manic Depressive Illness Depressed Patient Monoamine Oxidase Bipolar Patient Affective Change 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cotzias, G. C., Papavasiliou, P. S., and Gellene, R.: Modification of Parkinsonism-chronic treatment with L—DOPA, New England Journal of Medicine, 280: 338, 1969.CrossRefGoogle Scholar
  2. 2.
    Bunney, W. E., Jr., Janowsky, D. S., Goodwin, F. D., Davis, J. M., Brodie, H. K. H., Murphy, D.L., and Chase T.N.: Effect of L-DOPA on depression, Lancet, 1: 885, 1969.PubMedCrossRefGoogle Scholar
  3. 3.
    Bunney, W.E. and David J.M.: Norepinephrine in depressive reactions, Archives of General Psychiatry, 13: 483, 1965.PubMedCrossRefGoogle Scholar
  4. 4.
    Schildkraut, J. J.: The catecholamine hypothesis of affective disorders: A review of supporting evidence, American Journal of Psychiatry, 122: 509, 1965.PubMedGoogle Scholar
  5. 5.
    Klerman,G.L.,et al Clinical experience with dihydroxyphenylalanine (DOPA) in depression,Journal of Psychiatric Research,1:289,1963.Google Scholar
  6. 6.
    Goodwin, F.K., Murphy, D.L., Brodie, H.K.H., and Bunney, W.E., Jr.: L-Dopa catecholamines, and behavior: a clinical biochemical study in depressed patients, Biological Psychiatry, 2: 341, 1970.PubMedGoogle Scholar
  7. 7.
    Leonhard, K.: Aufteilung der Endogenen Psychosen, 2nd ed. Berlin, Akademie Verlag, 1959.Google Scholar
  8. 8.
    Bunney W.E., Jr., and Hamburg, D.A.: Methods for reliable longitudinal observation of behavior, Archives of General Psychiatry, 9: 280, 1963.PubMedCrossRefGoogle Scholar
  9. 9.
    Goodwin, F.K., Brodie, H, K. H., Murphy, D.K., and Bunney, W.E., Jr.: Administration of a peripheral decarboxylase inhibitor with L-DOPA to depressed patients, Lancet, 1: 908, 1970.PubMedCrossRefGoogle Scholar
  10. 10.
    Ashcroft, G. and Sharman, D.F.: Changes in the concentration of 5-OR indolyl compounds in cerebrospinal fluid and caudate nucleus, British Journal of Pharmacology, 19: 153, 1962.Google Scholar
  11. 11.
    Gerbode, F., and Bowers, W.: Measurement of acid monoamine metabolites in human and animal cerebrospinal fluid, Journal of Neurochemistry, 15: 1053, 1960.CrossRefGoogle Scholar
  12. 12.
    Kopin, I. J.: Metabolism and Disposition of Catecholamines in the Central and Peripheral Nervous Systems, in Levine, R. (Ed.) Endocrines and the Central Nervous System, Res. Publ. Nerv. Ment. Dis., Vol 43, Baltimore, Williams and Wilkins Company, 1966, pp. 343–353.Google Scholar
  13. 13.
    Murphy, D. L., Brodie, H. K. H., Goodwin, F. D., and Bunney, W. E., Jr.: L—Dopa: induction of hypomania in bipolar manic-depressive patients, Nature, 229: 135, 1971.PubMedCrossRefGoogle Scholar
  14. 14.
    Bunney, W. E., Jr., Brodie, H. K. H., Murphy, D. K., and Goodwin, F. K.: Psychopharmacological differentiation between two subgroups of depressed patients, Proceedings 78th Annual Convention of the American Psychological Association, 829, 1970.Google Scholar
  15. 15.
    Coppen, A., Noguera, R., Bailey, J., Burns, B. H., Swani, M. S. Hare, E. H., Gardner, R., and Maggs, R.: Prophylactic lithium in affective disorders, Lancet, 2: 275, 1971.PubMedCrossRefGoogle Scholar
  16. 16.
    Murphy, D. L. and Weiss, R.: Reduced monoamine oxidase activity in blood platelets from Bipolar depressed patients, American Journal of Psychiatry, 128: 1351, 1972.PubMedGoogle Scholar
  17. 17.
    Vanderwende, C.: Psychotic symptoms induced in mice by the intravenous administration of solutions of 3,4 dihydroxyphenylalanine (DOPA), Archives of International Pharmacodynamics, 137: 145, 1962.Google Scholar
  18. 18.
    Randrup. A., and Munkvad, I.: Aggressive Behavior, Garattini, S. and Sigg, E. B. (Eds.), New York, Wiley and Sons, Inc., 1969, p. 228.Google Scholar
  19. 19.
    Goodwin, F. K.: Psychiatric side effects of LevoDOPA in man, Journal of the American Medical Association, 218: 1915, 1971. Google Scholar

Copyright information

© Plenum Press, New York 1973

Authors and Affiliations

  • H. Keith Brodie

There are no affiliations available

Personalised recommendations